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composite of death, myocardial infarction (MI), ischemic stroke, and
repeat revascularization (RR).
RESULTS After multivariable adjustment, there were trend of
increased 5-year risk of MACCE in the DM patients (Hazard ratio [HR]
1.128, 95% conﬁdence interval [CI] 0.989-1.286 p¼0.072), mainly
driven by increased risk of hard outcomes (HR 1.445, 95% CI 1.164-
1.793, p¼0.001 for death; HR 1.289, 95% CI 1.067-1.558, p¼0.008 for
composite of death, MI, and stroke). However, the risk of repeat
revascularization was comparable between DM and non-DM patients
(HR 1.021, 95% CI 0.861-1.211, p¼0.808), despite of unfavorable pro-
cedural characteristics, including lesser complete revascularization
(36.5% vs. 39.0%, p¼0.082) and longer total stent length
(62.934.4mm vs. 60.033.1mm, p¼0.001). The risk of target lesion
revascularization (HR 1.146, 95% CI 0.913-1.440, p¼0.241) was also not
signiﬁcantly different between two groups.Outcomes Hazard ratio 95% conﬁdence interval P valueMACCE 1.128 0.989-1.286 0.072Death 1.445 1.164-1.793 0.001Myocardial infarction 0.615 0.357-1.060 0.080Stroke 0.931 0.585-1.480 0.761Death, myocardial
infarction, and stroke1.289 1.067-1.558 0.008Repeat revascularization 1.021 0.861-1.211 0.808Target vessel
revascularization1.143 0.930-1.406 0.204Target lesion
revascularization1.146 0.913-1.440 0.241New lesion
revascularization1.116 0.825-1.509 0.477Stent thrombosis 0.909 0.499-1.657 0.756MACCE, major adverse cardio and cerebrovascular event.
CONCLUSIONS Although risk of hard outcomes after PCI were still
higher in the DM patients, the risk of revascularization was compa-
rable between DM and non-DM patients in the era of DES.
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BACKGROUND It remains unclear whether there are differences in
the safety and efﬁcacy outcomes between everolimus-eluting stent
(EES) and zotarolimus-eluting stent (ZES) for treatment of unpro-
tected left main coronary artery stenosis.
METHODS From the IRIS MAIN Registry (total 4253 patients), we
identiﬁed 1402 consecutive patients who received EES (982 patients)
and ZES (420 patients). We compared major adverse cardiovascular
events (MACE) which was deﬁned as a composite measure consisting
of death, nonfatal myocardial infarction, or target vessel revasculari-
zation (TVR).
RESULTS Mean agewas 64.210.4 years and 65.010.6 years in the EES
and ZES groups, respectively(p¼0.22). Male made up 76.4% and 79.8%
(p¼0.17). Therewas nodifference in the prevalence of diabetes between
the two groups(p¼0.61). 2 year follow-upwas completed in 40.9%of the
EES group and 71.9% of the ZES group (p¼<0.001). At the 2-years of
clinical follow-up, the EES and ZES groups did not differ signiﬁcantly in
the risk of MACE (10.9% for EES vs 6.4% for ZES; hazard ratio [HR], 1.36;
95% conﬁdence interval [CI], 0.90–2.06, p¼0.14) with no difference in
the individual component of MACE - death (HR, 1.72; 95% CI, 0.72–4.12,
p¼0.22), MI (HR, 2.10; 95% CI, 0.47–9.34, p¼0.33), and TVR (HR, 1.21;
95%CI, 0.74–1.99, p¼0.44). The risk of cerebrovascular event (HR, 2.19 ;
95% CI, 0.49–9.78, p¼0.291) and deﬁnite stent thrombosis (HR, 0.004;
95% CI, 0.000 –564.85, p¼0.36) were also similar between the two
groups. The risk of MACE between the two groups remained similar
after adjusting for the difference in baseline characteristics, using the
multivariate Cox’s proportional hazard model.
Table. 2-year clinical outcomes following the use of EES versus ZESVariable EES (n[982) ZES (n[420) HR (95% CI) P valueMACE, n (%) 107 (10.9) 27 (6.4) 1.30 (0.85-1.99) 0.22Death, n(%) 33 (3.4) 6 (1.4) 1.72 (0.72-4.12) 0.22Cardiac death, n(%) 28 (2.9) 2 (0.5) 4.35 (1.03-18.30) 0.045Non-cardiac death, n (%) 5 (0.5) 4 (1.0) 0.40 (0.11-1.50) 0.17Myocardial infarction, n (%) 13 (1.3) 2 (0.4) 2.10 (0.47-9.34) 0.33Target vessel revascularization, n (%) 74 (7.5) 20 (4.8) 1.21 (0.74-1.99) 0.44Stent thrombosiss, n (%) 0 (0) 3 (0.7) 0.004 (0.000-564.85) 0.36Cerebrovascular event, n (%) 13 (1.3) 2 (0.5) 2.19 (0.49-9.78) 0.29EES, everolimus-eluting stent; HR, hazard ratio; MACCE, major adverse cardiac or cerebrovascular event;
MACE, major adverse cardiovascular event; ZES, zotarolimus-eluting stent
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left main coronary artery lesions showed similar outcomes with re-
gard to death, MI, and TVR.
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BACKGROUND This study sought to compare the clinical perfor-
mances of zotarolimus-eluting stents(ZES) and everolimus-eluting
stents (EES) for multi-vessel coronary artery disease.
METHODS From August 2006 to December 2013, a total of 1989
consecutive patients with multi-vessel coronary artery disease un-
derwent percutaneous coronary intervention (PCI) with ZES (N ¼
1,106) or EES (N ¼ 973) implantation in Asan Medical Center. Primary
outcome was deﬁned as the composite of death, myocardial infarc-
tion, or target vessel revascularization (MACE: major adverse cardio-
vascular event) at 3 years.
RESULTS The adjusted-risk of MACE (hazard ratio[HR], 0.88; 95%
conﬁdence interval[CI] 0.66-1.16, P¼0.36) did not differ between pa-
tient who received ZES and EES implantation at 3 years. The adjusted
risk of death (HR, 0.78; 95% CI, 0.54-1.15, P¼0.21), the composite of
death or myocardial infarction (HR, 0.79; 95% CI, 0.55-1.12, P¼0.18),
and target vessel revascularization (HR, 0.78; 95% CI, 0.69-1.62,
P¼0.79) were also similar between ZES and EES group. The 3-year
cumulative incidence of deﬁnite or probable stent thrombosis was
0.5% and 0.4% in ZES and EES group, respectively.
CONCLUSIONS The clinical performance of ZES and EES were not
signiﬁcantly different for patients with multi-vessel coronary artery
disease.
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BACKGROUND Little is known about the clinical follow-up after
sirolimus-eluting stent (SES) implantation and about the effect of SES
implantation in in-stent restenosis (ISR) lesion more than ﬁve years.
We aimed to compare clinical outcomes up to 10 years after SES im-
plantation in de novo lesion and ISR lesion.
METHODS A series of 392 patients underwent the ﬁrst SES im-
plantation between November 2002 and December 2004, whose
clinical outcomes were investigated. There were 253 patients for de
novo lesion and 139 patients for ISR lesion. We evaluated the out-
comes after SES implantation and clinical information was obtained
either from a review of the hospital records or by telephone in-
terviews with the patients, family members, or primary care
physicians.
RESULTS Mean follow up period was 10.0 years. Cumulative inci-
dence of major cardiac events (MACE) and target-lesion revasculari-
zation in ISR group were signiﬁcantly higher than that in de novo
group through 10 years (56.1% vs. 38.7%; p ¼ 0.01, and 41.3% vs.
20.6%; p ¼ 0.004, respectively) and the difference of the MACE and
TLR rate in two groups increased in this period. Cumulative incidence
of myocardial infarction (MI) and stent thrombosis (ST) between 2
groups were not signiﬁcantly different (13.0% vs. 7.9%; p ¼ 0.1, and
5.0% vs. 2.4%; p ¼ 0.15, respectively).
CONCLUSIONS The incidence of MACE and TLR after the SES im-
plantation in ISR lesion was signiﬁcantly higher than that in de novo
lesion and the difference of the TLR rate between in two lesions
became more clear through 10 years, although the incidence of MI and
ST had no signiﬁcant difference in 2 groups.
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